Document:

CONSULTING AGREEMENT 

 

THIS
AGREEMENT (“Agreement”), dated this __ day of August 2011, to be effective as of July 15, 2011 (the
“Effective Date”), confirms that RADEINT PHARMACEUTICALS CORPORATION, a Delaware corporation having
its principal place of business at 2492 Walnut Avenue, Suite 100, Tustin, CA 92780-7039, its subsidiaries and affiliates
(“The Company”) have retained BRIGHTON CAPITAL, LTD., a California corporation with its principal offices
at 1875 Century Park East, Suite, 700, Los Angeles, CA 90067 (“Brighton”), for the purposes described in this
Agreement in accordance with the terms and conditions specified herein, and Brighton has agreed to such engagement.

1.
Purpose of Engagement. Brighton will has rendered and will continue to render strategic advisory services (the “Services”)
as outlined below:

 

		•	Assist the Company with the restructuring of various
debt obligations including warrant conversions and or transactions that would increase the Company’s current cash position.

 

		•	Assist The Company in developing a business and marketing
strategy.

 

		•	Assist The Company in developing an acquisition strategy
and structure.

 

		•	Other services as mutually agreed to by The Company and
Brighton.

 

2.
Period of Engagement. Brighton’s engagement under this Agreement will commence on the date written above and expire
one hundred eighty (180) days later, unless mutually extended by the parties. Notwithstanding the foregoing, this Agreement may
be terminated by either party, at any time, with or without cause, upon thirty (30) days written notice to that effect to the
other party.

 

3.
Brighton’s Compensation.

 

(a)
The parties agree that, as of the Effective Date of this Agreement, the value of the Services rendered and to be rendered
to the Company under this Agreement is $106,000.

(b)  The Company upon execution of this Agreement shall pay to Brighton in cash $10,000 and shall issue to Brighton 1,200,000
common shares of the Company, valued at $96,000 based on the $0.08 per share closing price of such common shares as at the Effective
Date.

(c)
The shares shall be issued pursuant to the exemption from registration provided by Section 4(2) of the Securities Act and
the Company agrees to assist Brighton with the removal of any legends once the holding period and other requirements of Rule 144
have been satisfied. The shares shall immediately vest regardless of the services performed by Brighton or earlier termination
of this Agreement. The payments made hereunder are non-refundable and the shares are considered earned as of the date of this
Agreement.

(d) The Company, in its sole discretion, may make additional cash payments and or issue additional shares to Brighton based
upon the Brighton’s performance. 

(e)
The Company shall reimburse Brighton for all prior approved expenses.

 

The parties have caused this Agreement to be executed
by their duly authorized representatives as of the date written above.

 

    	Page 1 of 4

    	 

    
 

Engagement terms (including attached Exhibit A, Standard
Terms and Conditions) accepted by:

 

	RADIENT
    PHARMACEUTICALS	CORPORATION 
    BRIGHTON CAPITAL, LTD.
	 	 
	By: /s/ Douglas C. MacLellan	By: /s/ Jeffrey B. Wolin
	Name: Douglas C. MacLellan	Name: Jeffrey B. Wolin
	Title: Chief Executive Officer	Title: President

 

    	Page 2 of 4

    	 

    

EXHIBIT A

 

STANDARD TERMS AND CONDITIONS

1.
Accuracy of The Company Data. The Company recognizes and confirms that in performing its duties pursuant to this Agreement,
Brighton will be using and relying on data, material and other information (the “Information”) furnished by The Company,
and its employees and representatives and on information available from generally recognized public sources without any independent
investigation or verification thereof. Accordingly, Brighton assumes no responsibility for the accuracy and completeness of the
Information. The Company agrees that any Services will be based entirely upon Information supplied by The Company or available
from public sources. The Company will exercise reasonable care to ensure that Information is complete and accurate in all material
respects, and not materially misleading, and The Company will be solely responsible for the accuracy and completeness of any such
Information used, summarized or presented in any Services. Without limiting the foregoing, Brighton will be neither responsible
for nor liable to any party for any representations, assertions or statements based on the Information or reasonably derived therefrom
if such representations, assertions or statements prove to be false, inaccurate, deceptive, misleading or incomplete.

2.
Confidentiality. Unless required by law or applicable legal process, any advice rendered by Brighton pursuant to this Agreement
may not be disclosed publicly by Brighton or The Company without the other party’s prior written consent or used for any
purposes not related to The Company’s participation in the Services.

3.
Confidential and Proprietary Information. “Confidential and Proprietary Information” means all documents,
software, reports, data, records, forms and other material (a) obtained by Brighton from The Company in the course of
performing the Services: (i) that have been marked as confidential; (ii) whose confidential nature has been made known by The
Company to Brighton; or (iii) that due to their character and nature, a reasonable person under like circumstances would
treat as confidential or (b) developed or prepared by Brighton based upon information described in (a). Confidential and
Proprietary Information does not include information which: (i) is already known to Brighton at the time of disclosure by The
Company; (ii) is or becomes publicly known through no wrongful act of Brighton; (iii) is independently developed by Brighton
without benefit of The Company’s Confidential and Proprietary Information; or (iv) is received by Brighton from a third
party without restriction and without a breach of an obligation of confidentiality. All Confidential and Proprietary
Information of The Company remains the property of The Company and will be maintained in confidence by Brighton, will not be
used by Brighton for any purpose other than to provide the Services under this Agreement, and will not be disclosed to any
third party, except as provided herein, without The Company's prior written consent, unless required by applicable law or
legal process. At the conclusion of the Services, Brighton will, upon The Company’s request, return to The Company all
Confidential and Proprietary Information of The Company in its possession or, upon The Company's request, Brighton will
destroy all Confidential and Proprietary Information of The Company in its possession, subject to Brighton’s need to
preserve its interests hereunder. Upon written request by The Company, Brighton will certify the destruction of all
Confidential and Proprietary Information of The Company, clearly identifying any such information retained by Brighton as
necessary to preserve its interests hereunder. The confidentiality restrictions and obligations imposed by this section will
terminate two (2) years after the expiration or termination of this Agreement.

4.
Limitations on Use. The Company expressly acknowledges that all information and advice provided by Brighton to The Company
in connection with Brighton’s engagement are intended solely for the benefit and use of The Company (including its management,
directors, shareholders and attorneys) in considering the Services to which they relate, and The Company agrees that, except as
required by law, no such information or advice will be used for any other purpose or reproduced, disseminated, quoted or referred
to at any time, in any manner or for any purpose, nor will any public reference to Brighton be made by The Company (or such persons)
without the prior written consent of Brighton, which will not be unreasonably withheld. The Company specifically agrees, without
limiting the generality of the foregoing, that it will not use any information or advice provided by Brighton to The Company in
any tax matter, proceeding or audit nor in any matter having to do with the listing or public sale of securities unless Brighton
has agreed to such use beforehand, in writing.

5. Indemnification of Brighton.

(a)
In the event of a claim by a third party (including other Members of the Group) relating to services under the Agreement to which
these Standard Terms and Conditions are attached, The Company will indemnify Brighton and its personnel from all such claims,
liabilities, costs and expenses, except to the extent determined to have resulted from the intentional or deliberate misconduct
by Brighton.

(b)
Brighton will have no liability to The Company for any actions, damages, claims, liabilities, costs, expenses or losses in any
way arising out of or relating to the services performed hereunder for an aggregate amount in excess of the fees paid by The Company
to Brighton under this Agreement. In no event shall Brighton be liable for consequential, special, indirect, incidental, punitive
or exemplary damages, costs, expenses, or losses (including, without limitation, lost profits and opportunity costs). The provisions
of this Paragraph shall apply regardless of the form of action, damage, claim, liability, cost, expense, or loss, whether in contract,
statute, tort (including, without limitation, negligence) or otherwise.

(c)
In the event any third party asserts a claim against Brighton or its personnel for which a right of indemnification is asserted
under subparagraph (a) above, The Company shall, at its choice, either engage counsel to defend Brighton and/or its personnel
or shall be responsible for the current payment of costs and expenses Brighton and/or its personnel incur to defend against such
claim.

6.
Independent Contractor. Nothing in this Agreement will be deemed to constitute Brighton or The Company the agent of the other.
Neither Brighton nor The Company be or become liable or bound by any representation, act or omission whatsoever of the other.

7.
Not a Registered Broker-Dealer. Brighton is not a registered broker-dealer and will not be providing services to The Company
as a broker-dealer. All services provided by Brighton will be strictly as an advisor to The Company.

    	Page 3 of 4

    	 

    
 

8.
Nonassignability. This Agreement and all rights, liabilities and obligations hereunder will be binding upon and inure to the
benefit of each party’s successors, but neither party will assign, transfer or subcontract this Agreement or any of its
obligations hereunder without the other party’s express, prior written consent.

9.
Severability. In the event that any term or provision of this Agreement is held invalid, void or unenforceable, then the remainder
of this Agreement will not be affected, impaired or invalidated, and each such term and provision of this Agreement will be valid
and enforceable to the fullest extent permitted by law.

10.
Governing Law. Regardless of the place of execution or performance, this Agreement and any related indemnification and confidentiality
agreements between the parties will be deemed made in Delaware. All actions arising hereunder or in connection herewith will fall
under the exclusive jurisdiction and venue of the American Arbitration Association located in New York, NY and each of the parties
hereto hereby agrees to the personal jurisdiction and venue of said arbitrator. The parties hereto agree to service of process
by certified mail or receipted courier. Any right to trial by jury with respect to any claim or proceeding related to or arising
out of this engagement, or any transaction or conduct in connection herewith, is waived.

11.
Integration. This Agreement constitutes the entire agreement of the parties with respect to its subject matter and
supersedes all prior and contemporaneous representations, proposals, discussions, and communications, whether oral or in
writing. This Agreement may be modified only in writing and will be enforceable in accordance with its terms when signed by
each of the parties hereto.

12.
Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which will be deemed an original,
but all of which constitute one and the same instrument.

13.
Third Party Beneficiaries. This Agreement is made solely for the benefit of The Company, Brighton, other Indemnified Parties
and their respective successors and assigns, and no other person will acquire or have any right under or by virtue of this Agreement.

14.
No Conflict of Interest. The Company recognizes that Brighton may from time to time throughout the term of this Agreement
provide services to companies that are in competition with The Company. The Company hereby agrees that this Agreement does not
limit Brighton’s ability to provide such services, and that Brighton’s provision of such services does not represent
a breach of this Agreement or represent a conflict of interest for Brighton in the context of this Agreement. This paragraph does
not limit Brighton’s confidentiality obligations under paragraph 2 of this Agreement.

15.
Notices. All notices, requests and demands hereunder will be in writing and will be deemed to have been duly given (a) upon
personal delivery, (b) five (5) days after being mailed by registered or certified mail, return receipt requested or (c) one (1)
business day after being sent by nationally recognized overnight courier.

    	Page 4 of 4AMENDMENT TO CONSULTING AGREEMENT

 

THIS AMENDMENT to the Consulting Agreement entered into on
August __, 2011 (“Original Agreement”) whereby RADIENT PHARMACEUTICALS CORPORATION,
a Delaware corporation having its principal place of business at 2492 Walnut Avenue, Suite 100, Tustin, CA 92780-7039,
its subsidiaries and affiliates (“The Company”) retained BRIGHTON
CAPITAL, LTD., a California corporation with its principal offices at 1875 Century Park East, Suite, 700, Los Angeles,
CA 90067 (“Brighton”), to render strategic advisory services as defined in the Original Agreement, is hereby
made in order to amend Section 2of the Original Agreement with regard to Brighton’s Compensation.

 

In consideration for the mutual premises herein, the sufficiency
of which is hereby acknowledged, the parties hereto agree to the following amendment to Section 2:

 

(f) Brighton shall receive an additional 100,000,000 common
shares of the Company, in addition to the Compensation previously agreed to in the Original Agreement. 50% of these shares shall
be issued immediately and 50% shall be issued in equal installments over the next twelve (12) months.

 

(g) The Company
shall immediately issue the shares due and owing from the Original Agreement. All shares shall be deemed fully vested. 

 

(h) The shares described above shall
be subject to the anticipated reverse split(s), will not be registered and are only available for sale under rule 144 (6-month
hold).

 

By signing this Amendment, the Agreement
shall hereby be extended for 12 months beginning November 1, 2011 through October 31, 2012.

 

Except as otherwise set forth herein, all terms and conditions
in the Original Agreement shall remain in full force and effect and this Amendment shall not change or modify the Original Agreement
other than described above.

 

    	 

    	 

    

 

The parties have caused this Amendment
to be executed by their duly authorized representatives as of the date written above.

 

Dated: November 21, 2011

 

Amendment terms accepted by:

 

	Radient
    Pharmaceuticals Corporation	 	Brighton Capital, Ltd. 

   

	By:	 	 	By:	 

	Name:	Douglas C. MacLellan	 	Name: Jeffrey B. Wolin
	Title:	Chief Executive Officer	 	Title:President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}]]